Kelly Bouie
Family · Irving, TXNPI 1023561537
Payments from drug & device makers
Across 231 payments — averaging $19.77 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$599
- Indivior Inc.$598
- E.r. Squibb & Sons, L.L.C.$522
- Alkermes, Inc.$435
- Neurocrine Biosciences, Inc.$434
- Otsuka America Pharmaceutical, Inc.$395
- plus $2K from 11 others
What the payments were for
- Food & beverage$4,568100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 25 | $599 |
| Indivior Inc. | 27 | $598 |
| E.r. Squibb & Sons, L.L.C. | 23 | $522 |
| Alkermes, Inc. | 22 | $435 |
| Neurocrine Biosciences, Inc. | 24 | $434 |
| Otsuka America Pharmaceutical, Inc. | 27 | $395 |
| Johnson & Johnson | 16 | $370 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 16 | $301 |
| Teva Pharmaceuticals USA, Inc. | 18 | $281 |
| Lundbeck LLC | 11 | $215 |
| Vanda Pharmaceuticals Inc. | 11 | $206 |
| Axsome Therapeutics, Inc. | 6 | $140 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $16 |
| Sunovion Pharmaceuticals Inc. | 1 | $14 |
| Luye Pharma (USA) Ltd. | 1 | $14 |
| Noven Therapeutics, LLC | 1 | $14 |
| Braeburn Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- VRAYLAR$125
How this compares
$4,568 in reported general payments places this provider in the 90th percentile of 15,456 family providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Invega SustennaPaliperidone Palmitate | 33 | $85,841 |
| PerserisRisperidone | 33 | $78,008 |
| Abilify MaintenaAripiprazole | 24 | $69,060 |
| RexultiBrexpiprazole | 35 | $52,102 |
| CaplytaLumateperone Tosylate | 29 | $47,608 |
| AustedoDeutetrabenazine | 15 | $40,947 |
| TrintellixVortioxetine Hydrobromide | 58 | $29,366 |
| VraylarCariprazine Hcl | 14 | $20,659 |
| AuvelityDextromethorphan Hbr/Bupropion | 22 | $20,074 |
| Aripiprazole | 173 | $7,218 |
| Lurasidone Hcl | 13 | $6,836 |
| Oxcarbazepine | 115 | $5,431 |
| Quetiapine Fumarate ErQuetiapine Fumarate | 44 | $5,051 |
| Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl | 16 | $3,070 |
| Quetiapine Fumarate | 243 | $2,738 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Otsuka America Pharmaceutical, Inc.Abilify Maintena, Rexulti | $395 | $121,16159 claims |
| Johnson & JohnsonInvega Sustenna | $370 | $85,84133 claims |
| Indivior Inc.Perseris | $598 | $78,00833 claims |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $301 | $47,60829 claims |
| Teva Pharmaceuticals USA, Inc.Austedo | $281 | $40,94715 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $16 | $29,36658 claims |
| AbbVieVraylar | $599 | $20,65914 claims |
| Axsome Therapeutics, Inc.Auvelity | $140 | $20,07422 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 15,456 family providers in Texas.
Other family in Irving
- Susan BowlinIrving$164K
- Lashonda CraneHouston$3.4M
- David WeirDallas$959K
- Luba YammineHouston$479K
- Robin BeachHouston$428K
- Nirupama JeromeAustin$418K
- April LopezMcAllen$417K
- Linda MercadoHouston$211K
- Sarah AguilarHouston$199K
- Sie ThomasDallas$197K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.